HARPOON THERAPEUTICS INC (HARP)
US41358P2056 - Common Stock
Taking everything into account, HARP scores 2 out of 10 in our fundamental rating. HARP was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of HARP have multiple concerns. HARP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
HARP had negative earnings in the past year.
HARP had a negative operating cash flow in the past year.
In the past 5 years HARP always reported negative net income.
HARP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
HARP's Return On Assets of -64.08% is on the low side compared to the rest of the industry. HARP is outperformed by 62.79% of its industry peers.
HARP has a Return On Equity of -677.78%. This is amonst the worse of the industry: HARP underperforms 83.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.08% | ||
| ROE | -677.78% | ||
| ROIC | N/A |
ROA(3y)-65.35%
ROA(5y)-50.84%
ROE(3y)-515.97%
ROE(5y)-328.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HARP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HARP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HARP has more shares outstanding
HARP has more shares outstanding than it did 5 years ago.
HARP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
HARP has an Altman-Z score of -5.25. This is a bad value and indicates that HARP is not financially healthy and even has some risk of bankruptcy.
HARP has a Altman-Z score of -5.25. This is in the lower half of the industry: HARP underperforms 65.66% of its industry peers.
A Debt/Equity ratio of 1.96 is on the high side and indicates that HARP has dependencies on debt financing.
The Debt to Equity ratio of HARP (1.96) is worse than 82.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.96 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.25 |
ROIC/WACCN/A
WACC8.93%
2.3 Liquidity
HARP has a Current Ratio of 1.90. This is a normal value and indicates that HARP is financially healthy and should not expect problems in meeting its short term obligations.
HARP has a Current ratio of 1.90. This is in the lower half of the industry: HARP underperforms 79.46% of its industry peers.
A Quick Ratio of 1.90 indicates that HARP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.90, HARP is doing worse than 77.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.9 | ||
| Quick Ratio | 1.9 |
3. Growth
3.1 Past
HARP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.06%, which is quite impressive.
HARP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.11%.
Measured over the past years, HARP shows a very strong growth in Revenue. The Revenue has been growing by 114.07% on average per year.
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q86.86%
Revenue 1Y (TTM)16.11%
Revenue growth 3Y76.76%
Revenue growth 5Y114.07%
Revenue growth Q2Q-67.33%
3.2 Future
The Earnings Per Share is expected to grow by 14.65% on average over the next years. This is quite good.
Based on estimates for the next years, HARP will show a very strong growth in Revenue. The Revenue will grow by 23.74% on average per year.
EPS Next Y90.06%
EPS Next 2Y34.83%
EPS Next 3Y21.93%
EPS Next 5Y14.65%
Revenue Next Year8.24%
Revenue Next 2Y-23.33%
Revenue Next 3Y-16.53%
Revenue Next 5Y23.74%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
HARP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HARP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HARP's earnings are expected to grow with 21.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.83%
EPS Next 3Y21.93%
5. Dividend
5.1 Amount
No dividends for HARP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HARPOON THERAPEUTICS INC
NASDAQ:HARP (3/8/2024, 7:11:33 PM)
After market: 23 -0.01 (-0.04%)23.01
+0.02 (+0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap492.41M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.08% | ||
| ROE | -677.78% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.96 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.9 | ||
| Quick Ratio | 1.9 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y90.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.11%
Revenue growth 3Y76.76%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y